DEXCOM stock shares as income in the first quarter, growth of a new coating. News ad

Dexcom, Inc. NASDAQ: DXCM once again demonstrated his formidable position in Continuous glucose monitoring (CGM) Market, delivery Outstanding financial results of the first quarter of 2025 This is emphasized by its stable impulse. The company’s indicators, due to severe demand for products, successful innovations and strategic expansion of market access, strongly supports the ambitious trajectory until the end of 2025, which indicates a clear way to further strengthen its leadership in Diabetic technologyField

The strong start of Dexcom in the ambitious year

Dexcom today

$ 84.66 -0.68 (-0.80%)

As of 9/9/2025 203: 58

52-week range

$ 57.52

▼

$ 132.26

P/e ratio.

59.20

Value is valuable

$ 98,11

Dexcom income report for the first quarter of 2025 revealed a significant The growth of revenue reaches $ 1.036 billion. USAThe growth of 12% and 14% of organic growth in annual calculus is reported. This marks the second quarter in a row of accelerating growth of revenue. Organic income, with the exception of foreign exchange and non-CGM impact, amounted to $ 1.046 billion.

A The American market was a key driverWith an increase in revenue by 15% to 750.5 million dollars. USA, which indicates high internal demand. International markets also made a significant contribution, and 7% reported an increase in revenue by 12% to 285.5 million dollars. USA.

A noteworthy achievement was a record number of new customers, especially within Non -involved type 2 using the populationThis is emphasized by the expanding introduction of CGM technology at a wider base of patients. General Director Kevin Sayer It is stated in the income that Dexcom has achieved strong income results and provided significant new Type 2 In the first quarter.

This Strong performance Despite the short -term problems of supplies from the previous problem of shipment of the sensor, occurred. Dexcom Priority for customer service through a proactive connection, which helped normalize the levels of channels by the end of the 1st quarter of 2025.

In terms of profitability, Q1 2025 Gaap operational income was 133.7 million dollars (12.9% income) and nOperational income on-Gaap there were 143.1 million dollars (13.8% income). The company also reported the adjusted EBITDA 230.4 million dollarsrepresenting 22.2% income.

Dexcom Innovative Powers Powers Engines Extension of the Market

The leadership of the Dexcom market is supported by key innovations and advanced access. A Dexcom G7 15-day systemThe purified FDA after the first quarter of 2025 will be launched in H2 2025 with a long wear time and improved accuracy. A OTC Boseensor Stelolaunched in the first quarter of 2025 and is available on Amazon NASDAQ: Amznattracted 200,000 applications download With growing use among people with type 2 diabetes, pre -Aibet and users focused on health.

It is important to note that Dexcom has expanded the coverage: as of January 2025The two main PBM now cover Dexcom CGM for all patients with diabetes, with The third addition of the G7 coating in the summer of 2025This can expand access to CGM by Almost six million users are not insulin type 2 By the end of the year supported by the ongoing clinical testing. International growth is also accelerated, especially in Japan and Francethrough Dexcom One platform

The 2025 DEXCOM manual reflects strategic confidence

Dexcom supports a Strong prospectsRepeating its 2025 in 2025 Revenger guide of 4.60 billion US dollarsrepresenting an approximate increase of 14% during 2024. The launch of the Stelo OTC device, according to forecasts, will contribute 2-3% to this growthField

While the purpose of the income remains unchanged, Dexcom revised his GAAP gross profit guide by about 62%reduction compared to the previous range of 64-65%. This adjustment is associated with short -term investments aimed at supporting long -term expansion. These investments include the impact of the results of the first quarter oriented on the offer of customers, constant accelerated costs of freight transportation for rapid replenishment of internal reserves to a 60-90-day offer to meet the growing demand and premature planning of indirect consequences of indirect tariffs for expenses for the supply and volatility of the currency course.

It is noteworthy that the company confirmed it Operating manual not GAAP by about 21% And this is adjusted EBITDA margins by about 30%This is emphasized by Dexcom to effectively control the total costs and use the effectiveness of operation, including the inclusion of artificial intelligence (AI) and robotics to soften the expected pressure on gross profit. The management indicated that the plans for significant investments in operating expenses exceed $ 100 million per year, while reaching these goals of margin.

Demonstrating confidence in its internal value and strong generation of funds, Dexcom announced a new Promoting Program program 750 million US dollars May 1, 2025. The company completed the first quarter with a significant $ 2.7 billion. USA in cash, cash equivalents and market securitiesProviding significant financial resources for strategic efforts.

Why is the narrative about dexcom only begins

Dexcom’s The performance of the first quarter And strategic initiatives provide a convincing picture of the company that firmly controls its market and its future. A combination of financial performance, pipeline filled with effective innovations, strategic expansion The steel platformAnd transforming access to the market conquers Dexcom positions for sustainable, healthy growth.

The ambitious but well -supported management of the 2025 company, even though it has strategic investment influencing The nearest gross marginsReflects a confident team of leadership. Dexcom seems to be ready not only to support, but also to expand its dominance in a rapidly developing and more and more important Diabetic technology landscapeOffering a strong look for investors that control this dynamic sector.

Before considering Dexcom, you will want to hear this.

Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and Dexcom was not on the list.

While Dexcom is currently a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.

View five shares here

If the company general, COO and financial director of the company sold shares, would you like to know? Marketbeat has just made its list of twelve actions that corporate insiders refuse. Fill in the form below to see which companies compiled the list.

Get this free report